Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Partnership Expands For Discovery Of Novel Cancer Treatments

By Bayer AG | December 1, 2017

Bayer and the Broad Institute of MIT and Harvard expand partnership to advance drug discovery research for novel cancer treatments.

Bayer and the Broad Institute of MIT and Harvard announced today that they have extended their multi-disciplinary research partnership by an additional five years, to develop and advance novel cancer treatments.

The expanded agreement will focus on a defined goal to jointly identify three new additional investigational drugs (INDs) for novel oncology targets. 

Established in 2013, the partnership brings together the Broad Institute’s expertise in cancer research and chemical biology with Bayer’s in-depth experience in small, chemically manufactured molecules and biologics drug discovery.

In 2015, the collaboration was expanded to examine genomics and drug discovery in cardiovascular disease. With this recent extension, the Broad Institute will also bring their expertise in biomarker development and patient selection and clinical trial design.

Now extended to 2023, the Bayer-Broad collaboration is uniquely structured to encourage close coordination and ongoing, face-to-face interactions between researchers at both organizations. For example, an alliance manager from Bayer is located at the Broad Institute to help coordinate projects and ensure researchers have rapid access to information.

The research is guided by joint project and governance teams. In addition to identifying investigational drugs for novel oncology targets and generating the associated intellectual property, the institutions will continue to openly share the biological knowledge generated with the scientific community, including through publicly available datasets and publications in academic journals.

“Ultimately it means a greater chance of making critical discoveries, and rapidly delivering on these findings, so we can reach patients,” Todd Golub, chief scientific officer of the Broad Institute, said.

(Source: Bayer AG)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE